Table 1.

Clinical characteristics of dermatomyositis (DM) patients with anti-DFS70 antibodies in our cohort.

Patient	Sex/Age, yrs	Diagnosis	Complication	Prognosis	Skin Symptoms			Elevation of CK^*	Anti-DFS70 Titer, U/ml	DM Marker Autoantibodies	Other Autoantibodies
Patient	Sex/Age, yrs	Diagnosis	Complication	Prognosis	H	G	C	Elevation of CK^*	Anti-DFS70 Titer, U/ml	DM Marker Autoantibodies	Other Autoantibodies
1	F 25	CADM	—	Surviving	⁺	⁺	⁻	⁻	101.4	MDA5	p80-coilin⁸
2	F 23	CADM	ILD	Surviving	⁺	⁺	⁻	^+/−	43.2	MDA5	—
3	F 46	CADM	ILD	Dead	⁺	⁺	⁻	^+/−	29.7	MDA5	—
4	F 68	Cancer-associated DM	Ovarian carcinoma	Dead	⁺	⁺	⁻	⁺	28.0	NXP-2	—
5	M 1	Juvenile DM	—	Surviving	⁻	⁺	⁺	⁺	50.4	TIF1-γ	—
6	F 6	Juvenile DM	Atopic dermatitis	Surviving	⁺	⁺	⁻	⁻	30.2	Unidentified	—
7	F 46	Classical DM	—	Surviving	⁺	⁻	⁻	⁺	18.9	—	—

↵* Maximum elevation of creatine kinase (CK) is shown;
↵+: more than 1.5-fold of upper limit;
↵+/−: within 1.5-fold of upper limit;
↵−: within upper limit. H: heliotrope rash; G: Gottron’s sign; C: calcinosis; CADM: clinically amyopathic dermatomyositis; ILD: interstitial lung disease.